New Recombinant Tuberculosis BCG Vaccine for Immunocompromised Patients and Others
- Technology Benefits
- Safer and more effective vaccine for the treatment of TB in immunocompromised individuals and others More efficacious than the currently available vaccine.
- Technology Application
- A safer and more potent vaccine against TB.
- Detailed Technology Description
- UCLA researchers have developed novel rBCG30 vaccines that are growth restricted in the immunized individual. These new vaccines are comparable to rBCG30 in potency, but unlike both BCG and rBCG30, they are unable to multiply more than a few times in the host and, consequently, they are unable to cause disease in the host, even in a severely immunocompromised individual. Like rBCG30, the new vaccines are more effective than BCG, the current vaccine, in the highly relevant and stringent outbred guinea pig model of pulmonary tuberculosis, a model that closely mimics human tuberculosis.
- Supplementary Information
- Patent Number: US8163294B2
Application Number: US2008296660A
Inventor: Horwitz, Marcus A. | Tullius, Michael V.
Priority Date: 16 Oct 2003
Priority Number: US8163294B2
Application Date: 22 Apr 2009
Publication Date: 24 Apr 2012
IPC Current: A61K003904 | A61K003902 | A61K004900
US Class: 4242481 | 4240091 | 4240092 | 4241841 | 4241921 | 4242001 | 4242341
Assignee Applicant: The Regents of the University of California
Title: Growth regulatable recombinant BCG compositions
Usefulness: Growth regulatable recombinant BCG compositions
Summary: The immunogenic composition comprising a growth regulatable recombinant Bacille Calmette Guerin (rBCG) expressing at least one Mycobacteria major extracellular protein is useful as vaccine against pathogenic bacteria, e.g., Mycobacterium bovis .
- Industry
- Biomedical
- Sub Category
- Pathogen
- Application No.
- 8163294
- Others
-
State of Development
This vaccine has been tested and proven effective in guinea pigs.
Background
The only currently available TB vaccine, an attenuated Mycobacterium bovis strain Bacille Calmette-Guerin (BCG), is of variable efficacy. A large carefully conducted meta-analysis has estimated the potency of BCG to be approximately 50%. UCLA researchers developed and reported in the last several years a recombinant BCG expressing the Mycobacterium tuberculosis 30 kDa major secretory protein (r30). This vaccine, named rBCG30, induces greater protection than BCG against aerosol challenge with a highly virulent strain of M. tuberculosis.Immunocompromised individuals, such as HIV infected persons, are more susceptible to TB, and HIV infection significantly increases TB mortality. BCG has been used to vaccinate immunocompromised persons; however the live BCG vaccine can disseminate in an immunocompromised host and cause serious illness and even death. Therefore a safer TB vaccine is desired for immunocompromised individuals.
Additional Technologies by these Inventors
- Recombinant Tuberculosis BCG Vaccine Elicits a Highly Protective Host Immune Response
- Method of Producing Novel Unmarked Recombinant Vaccine Vector for Tuberculosis
- Safe and Potent Vaccines against Tularemia
- Novel Vaccines Against Tularemia
- Improved Immunization Strategy Using Recombinant BCG Vaccines
- Novel Live Recombinant Booster Vaccine against Tuberculosis
- Live Recombinant Tuberculosis Vaccine
Tech ID/UC Case
20145/2006-539-0
Related Cases
2006-539-0
- *Abstract
-
UCLA researchers specializing in infectious diseases have developed an improved and safer method for producing recombinant vaccines that prevent or treat tuberculosis (TB) in immunocompromised patients and others.
- *IP Issue Date
- Apr 24, 2012
- *Principal Investigator
-
Name: Marcus Horwitz
Department:
Name: Michael Tullius
Department:
- Country/Region
- USA
